Swedish health-tech company Brighter AB (Nasdaq First North Growth Market:BRIG) said on Wednesday that it has signed an agreement with the Northern Care Alliance NHS Foundation Trust in the UK for a funded-research study with Actiste Diabetes Management as a Service (ADMS) in the city of Salford.

This study is a high-level clinical-research project that the company hopes will confirm scientifically relevant insights about the benefits that Actiste can provide for the management of both type 1 and type 2 insulin-treated diabetes.

The research data will be shared with the diabetes scientific community, front-line care providers, patients, health-insurance companies and partners.